Advertisement

CheckMate 816: Neoadjuvant Nivolumab Plus Chemotherapy in Resectable NSCLC
Posted: 04/27/2022 | By: Matthew Stenger

Question 1 of 5

Nivolumab plus chemotherapy produced pathologic complete response (pCR) in:

Choose 1

A
43.0% of patients
B
24.0% of patients
C
21.2% of patients
D
46.3% of patients

CategoriesView All Quizzes

Tumor Type


Additional Topics



Conference Coverage